Objectives: To relate the enrichment of linezolid-resistant Enterococcus faecium with linezolid pharmacokinetics, the pharmacodynamics of linezolid and its ability to prevent the selection of resistant mutants were studied in an in vitro model that simulates antibiotic concentrations in and out of the mutant selection window (MSW), i.e. the concentration range from the MIC to the mutant prevention concentration (MPC).
Introduction
Linezolid is a new oxazolidinone antibiotic active against Gram-positive cocci including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. However, despite its relatively recent clinical introduction, linezolid-resistant S. aureus 1 and E. faecium 2 -4 have been isolated from patients who received prolonged courses of the drug. Recent attempts in our laboratory to enrich resistant S. aureus exposed in vitro to fluctuating concentrations of linezolid in a dynamic model that simulates antibiotic pharmacokinetics were unsuccessful, 5, 6 possibly because of small numbers of resistant cells in the starting inoculum. The aim of this study was to use the same model to detect linezolid-resistant E. faecium at antibiotic concentrations in and out of the mutant selection window (MSW) 7 and to evaluate the ability of doxycycline to prevent the enrichment of resistant enterococci.
Materials and methods

Antimicrobial agents, bacterial strain and susceptibility testing
Linezolid and doxycycline powders were provided by Pfizer, Inc. (Groton, CT, USA). A vancomycin-resistant clinical isolate of E. faecium, strain 392, was used for this study; vancomycin MIC was 80 mg/L, linezolid MIC was 1.8 mg/L, and doxycycline MIC was 0.20 mg/L. Susceptibility testing was performed by broth macrodilution techniques with the organism grown in brain -heart infusion (BHI) broth at an inoculum size of 5 Â 10 5 cfu/mL. The mutant prevention concentrations (MPCs) were determined as described elsewhere. 7 Briefly, the tested microorganisms were cultured in fresh BHI broth and incubated overnight at 368C. Then, two 50 mL aliquots were centrifuged at 2000 rpm for 30 min. The supernatant was discarded and the remaining pellets resuspended in 3 mL of fresh BHI. The 3 mL aliquots were thoroughly vortexed and combined in one tube to yield a concentration of 10 10 cfu/mL. From the combined 6 mL suspension, one to eight dilution steps were made in sterile saline and 200 mL from each dilution step was plated on antibiotic-containing Trypticase soy agar (TSA) supplemented with 4% sheep blood (SB) plates that were prepared in our laboratory. Concentrations for the linezolid plates ranged from 1.80 to 46.15 mg/L, and from 0.20 to 5.12 mg/L for doxycycline. The inoculated plates were incubated for 48 h at 368C and screened visually for growth. To estimate the MPC, logarithms of bacterial numbers were plotted against antibiotic concentrations. MPC was taken as the point where the plot intersected the x-axis, i.e. the lowest antibiotic concentration that completely inhibited growth when $10 10 cells were tested. The MPCs of linezolid and doxycycline were estimated at 7 and 3.4 mg/L, respectively.
In vitro dynamic model and simulated pharmacokinetic profiles A previously described dynamic model 8 was used in the study. Briefly, this two-compartment model consists of a central compartment and three bioreactors, artificial chambers (Fibercell Systems Inc., Frederick, MD, USA) connected in series, which represent the peripheral compartments. For all experiments, the bacterial inoculum was prepared from previously frozen inocula by thawing, diluting with an equal part of BHI and incubated for 90 min at 368C to bring the organisms into growth phase.
This mixture was then inoculated into each peripheral compartment, which also contained BHI, via an entry port and incubated until a density of $10 8 cfu/mL was achieved, at which time the antibiotic was introduced into the central compartment (time zero). Given a 20 mL volume of the peripheral compartment, the total number of organisms in the starting inoculum reached $2 Â 10 9 cfu. Control experiments without antimicrobial agent were performed to characterize growth kinetics. All dynamic model experiments were performed in triplicate.
A series of monoexponential profiles that mimic twice-daily administration (60 min infusion) of linezolid (half-life 6 h) 9 and once-daily doxycycline (half-life 15 h) 10 alone and in combination (1:3 ratio based on 24 h AUC/MICs) were simulated for 3 consecutive days. Overall, six dosing regimens were simulated: linezolid AUC 24 /MIC 60 h; linezolid AUC 24 /MIC 120 h; linezolid AUC 24 / MIC 240 h; doxycycline AUC 24 /MIC 240 h; doxycycline AUC 24 / MIC 720 h; linezolid AUC 24 /MIC 60 hþdoxycycline AUC 24 /MIC 240 h.
To provide simultaneous monoexponential elimination of linezolid and doxycycline, a previously described dynamic model was modified according to Zinner et al.
11
As the antimicrobial effect depends on antibiotic concentration in the peripheral compartments (where the organisms come into contact with antibiotic), peripheral compartments were sampled to determine linezolid concentrations by bioassay using well plates of TSA seeded with a clinical strain of coagulase-negative Staphylococcus and doxycycline with bioassay well plates of Antibiotic Medium #8 seeded with Bacillus cereus ATCC 11778.
Quantification of the antimicrobial effect and susceptibility changes
In each experiment, the peripheral compartments were sampled to determine bacterial concentrations. The numbers of surviving organisms were determined by serial dilution of samples in cold sterile saline and inoculating 20 mL in triplicate onto commercially available Mueller -Hinton agar supplemented with 5% SB. After overnight incubation at 368C, the resulting bacterial colonies were counted and the numbers of cfu/mL were calculated. The detection limit was 10 cfu/mL. The duration of the experiments was defined as the time (after the last dose) until antibiotic-exposed bacteria reached the same maximum numbers as observed in the absence of antibiotic (!10 9 cfu/mL). On the basis of the time-kill data, the intensity of the antimicrobial effect (I E -the area between control growth and time-kill curves) 12, 13 was determined from time zero to the time after the last antibiotic dose at which the number of antibiotic-exposed bacteria reached 10 8 cfu/mL. Changes in susceptibility of E. faecium 392 were examined by repeated MIC determinations and by plating a standard loopful of each 24 h specimen on TSA-SB plates containing no antibiotic, 2ÂMIC, 4ÂMIC, 8ÂMIC and 16ÂMIC of linezolid or doxycycline. The stability of observed resistance was determined daily by consecutive passaging E. faecium on antibiotic-free agar plates for 5 consecutive days.
Results
Pharmacodynamics and resistance in single-drug treatments with linezolid
Simulated pharmacokinetics and killing kinetics of linezolid-exposed E. faecium are presented in Figure 1 . As seen in the top panel of the figure, the estimated AUC 24 /MIC ratios were close to the target values: 70 h versus 60 h, 100 h versus 120 h, and 230 h versus 240 h. At the lowest AUC 24 /MIC, linezolid concentrations fell in the MSW for most of the dosing interval: after the first dose, the time within the MSW (T MSW ) was 100% of the interval. At the intermediate AUC 24 /MIC, linezolid concentrations were within the MSW for a shorter period: T MSW of 70%, whereas at the highest AUC 24 /MIC, the simulated concentrations were above the MPC throughout the dosing interval (out of the MSW): T MSW approached zero. The bottom panel of Figure 1 shows similar patterns of the time -kill curves: a gradual decrease in viable counts over 80 h (AUC 24 /MIC 70 h), 90 h (AUC 24 /MIC 100 h) and 100 h (AUC 24 /MIC 230 h) was followed by bacterial regrowth. The respective I E s were AUC 24 / MIC-dependent: the higher the AUC 24 /MIC, the greater the I E (see diagram in the right corner of the figure). The AUC 24 / MIC-response relationship was log-linear (data not shown).
Population analysis of specimens sampled from peripheral units of the dynamic model demonstrates a clear relationship between the enrichment of resistant mutants and simulated pharmacokinetics of linezolid (Figure 2) . Treatments of E. faecium at AUC 24 /MIC of 70 and 100 h that provide antibiotic concentrations within the MSW over at least a part of the first dosing interval (T MSW 100% and 70%, respectively) were accompanied by bacterial growth on the antibiotic-containing plates. This growth in the presence of 2Â, 4Â and 16ÂMIC, but not 8ÂMIC of linezolid, began earlier at AUC 24 /MIC of 70 rather than 100 h. The concomitant loss in susceptibility observed by 72 -96 h after the start of treatment was more pronounced at AUC 24 /MIC ¼ 70 h ( post-exposure MIC 2.2-fold higher than the pre-exposure MIC) than at AUC 24 /MIC ¼ 100 h (1.5-fold difference between pre-and post-exposure MICs). This loss at both simulated AUC 24 /MICs was unstable: the differences between pre-and post-exposure MICs disappeared after six passages (data not shown). Unlike the lower AUC 24 /MICs, at the highest AUC 24 /MIC ratio (230 h) when antibiotic concentrations were out of the MSW, the starting population was not enriched by resistant mutants and the susceptibility of E. faecium was not changed.
Pharmacodynamics and resistance in combined treatments with linezolid and doxycycline
Comparative killing kinetics of E. faecium in treatments with linezolid and doxycycline given alone and in combination are shown in Figure 3 . As seen in the figure, despite the rapid initial killing of E. faecium exposed to doxycycline, its effect was Figure 3 ), the combination of linezolid with doxycycline was synergistic: the I E that reflects the effect of combined treatment was 4.5 times greater than the sum of linezolid and doxycycline I E s in the single-drug treatments.
The studied combination also appeared to be efficient in preventing the selection of linezolid-resistant E. faecium. As seen in Figure 4 (left-hand panel), organisms resistant to 2ÂMIC were enriched much later in the combined treatment than with linezolid monotherapy at the same AUC 24 /MIC. Moreover, enterococci resistant to the higher linezolid concentrations (4Â, 8Â and 16ÂMIC) were not enriched at all in the presence of doxycycline, with no loss in susceptibility of antibioticexposed E. faecium. In contrast, the selection of doxycyclineresistant organisms also began later in combinations with linezolid, but it occurred at all doxycycline concentrations (from 2ÂMIC to 16ÂMIC) (Figure 4, right-hand panel) .
The described effects of linezolid on doxycycline pharmacodynamics and the emergence of enterococcal resistance to doxycycline could not be achieved by using a greater AUC 24 /MIC ratio of doxycycline given alone. As seen in Figure 5 , an almost 4-fold increase in the simulated AUC 24 /MIC (from 230 to 720 h) with T MSW s of 100% and 35% of the first dosing interval, respectively (upper panel), provided only a 1 day delay in regrowth of the doxycycline-susceptible subpopulation with similar minimal numbers of surviving organisms (upper middle panel). In contrast to these minor differences between the timekill curves, the combination of doxycycline (AUC 24 /MIC 230 h) with linezolid (AUC 24 /MIC 70 h) delayed regrowth for 4 days and yielded a much smaller minimal number of survivors. Similarly, at the increased AUC 24 /MIC (720 h), the amplification of E. faecium resistant to 2Â -16ÂMIC of doxycycline occurred at the same time as at the lower AUC 24 /MIC (230 h)-both much earlier than with the combined treatment-see the lower middle panel in Figure 5 showing the respective data on plates with 4ÂMIC of doxycycline. Similar data were obtained on antibiotic-containing plates at 2Â, 8Â and 16ÂMIC (data not shown). Minimal differences in the amplification of resistant E. faecium exposed to the smaller and larger AUC 24 /MICs of doxycycline are in concordance with similar concomitant changes in susceptibility of doxycycline-and doxycycline plus linezolid-exposed organisms ( Figure 5, bottom panel) . At both AUC 24 /MICs, the MICs of doxycycline increased 3 days earlier with doxycycline monotherapy than with the doxycycline/ linezolid combination, although a similar loss in doxycycline susceptibility (30-to 35-fold difference between pre-exposure and post-exposure MICs) occurred in all treatments.
Discussion
This in vitro study demonstrates concentration-dependent pharmacodynamics of linezolid and selection of linezolid-resistant mutants, in this case with E. faecium. A log-linear relationship was established between the intensity of the antimicrobial effect and simulated AUC 24 /MIC ratios in 3 day treatments with linezolid. In concordance with the MSW hypothesis, 7 E. faecium mutants resistant to 2 -16ÂMIC of linezolid were enriched when the antibiotic concentrations were within the MSW (AUC 24 /MIC 70 and 100 h), but not when concentrations were out of the MSW (AUC 24 /MIC of 230 h). The estimated 'anti-mutant AUC 24 /MIC ratio' is comparable to those reported in our studies with fluoroquinolone-and glycopeptide-exposed S. aureus (201 -244 h 14 and 200 h 15 ) and with moxifloxacinexposed Streptococcus pneumoniae (.100 h), 16 as well as in a similar in vitro study with garenoxacin-exposed S. aureus (190 h). 17 Given these consistent findings to other antibioticpathogen pair organisms, it is unclear why linezolid-resistant S. aureus did not emerge resistance in a similar experimental setting. 5, 6 In the present study with a specific strain of E. faecium, an AUC 24 /MIC ratio .200 h was estimated to protect against the selection of linezolid-resistant enterococci. This estimated value is two times larger than the AUC 24 /MIC of 100 h (186 mgÂh/L 9 /1.8 mg/L) that can be provided by a 600 mg clinical dose of twice-daily linezolid. One approach for restricting resistance is the use of linezolid in combination with other antibiotics. The combination of linezolid plus doxycycline (both at AUC 24 /MICs at which amplification of resistant E. faecium occurred in monotherapy) appears promising. Doxycycline was shown to strengthen the effects of linezolid on both susceptible and resistant E. faecium subpopulations. Unlike monotherapy, organisms resistant to 2ÂMIC of linezolid were enriched only after the end of the combined treatment, and those resistant to 4-16ÂMIC were not enriched at all. In contrast to linezolid-resistant staphylococci, the combined use of linezolid with doxycycline was able to delay the selection of enterococcal mutants resistant to 4-16ÂMIC of doxycycline, but did not prevent it. This can be explained by the fact that the simulated concentrations of linezolid (AUC 24 /MIC ¼ 70 h) were within its MSW over only part of the dosing interval, whereas concomitant concentrations of doxycycline (AUC 24 /MIC ¼ 240 h) were within its MSW over the entire dosing interval. Although linezolid influenced the pharmacodynamics of doxycycline to a lesser extent than doxycycline did with linezolid, the linezolid-induced delay in the selection of doxycycline-resistant enterococci was much more pronounced than what could be provided by a 4-fold greater doxycycline AUC 24 /MIC ratio given alone. Earlier, a similar combination of suboptimal AUC 24 /MICs of moxifloxacin and doxycycline, i.e. AUC 24 /MICs smaller than the anti-mutant values, was shown to prevent the enrichment of resistant staphylococci. 18 On the basis of the comparison of I E s determined in simulations of the pharmacokinetics of linezolid and doxycycline given alone and in combination, the combination's effect on the susceptible subpopulation of E. faecium was synergistic. Recently, similar synergism was reported in our pharmacodynamic studies with the same combination against S. aureus. 5, 6 These findings are consistent with a clinical report on bacteriologic cure of a neutropenic patient with fever caused by VRE with the addition of doxycycline to linezolid after unsuccessful monotherapy with daptomycin and linezolid. 2 These data are not consistent with an in vitro study with E. faecium 19 that demonstrated only minimal if any advantages of the linezolid/ doxycycline combination in a relatively short 48 h simulation.
Overall, these data suggest that linezolid-resistant enterococci are enriched when drug concentrations fall into the MSW and that the amplification of resistant mutants may be restricted by using linezolid in combination with doxycycline, even if both agents are given at suboptimal individual doses.
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